Drug Profile
KW 1
Alternative Names: KW-1Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Hepatitis B in China (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-B in China (Parenteral, Injection)
- 20 Feb 2013 Beijing Kawin Technology Share-Holding has patent protection for Recombinant plasmid DNA vaccine composition for treating Hepatitis B in China